These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19549693)

  • 21. Peritoneal membrane structural and functional changes during peritoneal dialysis.
    Goffin E
    Semin Dial; 2008; 21(3):258-65. PubMed ID: 18363601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. At-home dialysis: consider the advantages.
    Johns Hopkins Med Lett Health After 50; 2004 Nov; 17(9):3, 7. PubMed ID: 15609440
    [No Abstract]   [Full Text] [Related]  

  • 23. What are the problems with using the peritoneal membrane for long-term dialysis?
    Bargman JM; Krediet RT; Lo WK; Selgas R; del Peso G; Auxiliadora Bajo M; Mujais S
    Semin Dial; 2008; 21(1):11-23. PubMed ID: 18251949
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical practice protocol update in peritoneal dialysis-2004].
    Sansone G; Cirugeda A; Bajo MA; del Peso G; Sánchez Tomero JA; Alegre L; Hernández Y; Polanco N; Delgado Mallén P; Soares C; Hevia C; Selgas R
    Nefrologia; 2004; 24(5):410-45. PubMed ID: 15648901
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis.
    Li PK; Cheng YL
    Perit Dial Int; 2007 Jun; 27 Suppl 2():S158-63. PubMed ID: 17556296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revisiting the peritoneal dialysis dose.
    Moran J; Correa-Rotter R
    Semin Dial; 2006; 19(2):102-4. PubMed ID: 16551285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The patient with chronic renal failure].
    Schammann T; Schindler R
    Med Monatsschr Pharm; 2008 Nov; 31(11):417-26; quiz 427-8. PubMed ID: 19055161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ambulatory or home peritoneal dialysis--time for changes?].
    Pietrzak B; Baczyński D; Prokopiuk-Wierzbicka M; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):338-9. PubMed ID: 18634369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drastic change in protein intake may cause a rapid decline of residual renal function after initiation of peritoneal dialysis.
    Sogawa Y; Kadoya H; Kashihara N
    Ther Apher Dial; 2020 Dec; 24(6):736-738. PubMed ID: 32255551
    [No Abstract]   [Full Text] [Related]  

  • 30. [Biocompatibility of dialysis fluid in peritoneal dialysis--limitations and possibilities of improvement].
    Olszowska A; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):364-7. PubMed ID: 18634375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resumption of peritoneal dialysis after transcutaneous treatment of a peritoneal leakage using fibrin glue.
    Herbrig K; Pistrosch F; Gross P; Palm C
    Nephrol Dial Transplant; 2006 Jul; 21(7):2037-8. PubMed ID: 16520352
    [No Abstract]   [Full Text] [Related]  

  • 32. [Composition of amino acid in blood and dialysate by patients with in chronic renal insufficiency by peritoneal dialysis].
    Pichugina IS; Gapparov MM; Chukarina EV; Vetchinnikova ON; Vatazin AV
    Vopr Pitan; 2008; 77(3):45-8. PubMed ID: 18669331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. We Use Bioincompatible Peritoneal Dialysis Solutions.
    Troidle L; Hansson J; Juergensen P; Finkelstein FO
    Semin Dial; 2016 Jul; 29(4):263-4. PubMed ID: 27061506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients.
    Woodrow G
    Perit Dial Int; 2006; 26(1):113-4. PubMed ID: 16541510
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients.
    Brown F; Johnson DW
    Perit Dial Int; 2006; 26(1):112-3; author reply 114. PubMed ID: 16538887
    [No Abstract]   [Full Text] [Related]  

  • 36. Cystatin C and residual renal function in patients on peritoneal dialysis.
    Mulay A; Biyani M; Akbari A
    Am J Kidney Dis; 2008 Jul; 52(1):194-5; author reply 195-6. PubMed ID: 18589221
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chronic kidney failure: problems of pathogenesis and treatment].
    Ermolenko VM
    Ter Arkh; 1982; 54(7):114-8. PubMed ID: 6753210
    [No Abstract]   [Full Text] [Related]  

  • 38. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients.
    Schiffl H
    Nephrol Dial Transplant; 1995; 10(6):911-2. PubMed ID: 7566634
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chronic kidney failure].
    Laville M
    Rev Prat; 2001 Oct; 51(16):1833-40. PubMed ID: 11795131
    [No Abstract]   [Full Text] [Related]  

  • 40. Profiles of automated peritoneal dialysis prescriptions in the US 1997-2003.
    Mujais S; Childers RW
    Kidney Int Suppl; 2006 Nov; (103):S84-90. PubMed ID: 17080117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.